Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$11.28 USD
-0.02 (-0.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ENTA 11.28 -0.02(-0.18%)
Will ENTA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTA
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
ENTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Other News for ENTA
Enanta Pharmaceuticals to Participate in Investor Conferences in September
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Buy Rating Affirmed on Enanta Pharmaceuticals’ Promising Drug Pipeline and Strategic Expansion into Immunology
Oppenheimer Sticks to Their Hold Rating for Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution